Table 2

Cardiovascular outcomes in the ORIGIN trial (21,22): effect of normalization of fasting plasma glucose and A1C by evening insulin glargine administration

GroupsOutcomesHazard ratio (95% CI)P
Insulin glargine vs. standard careCardiovascular death, nonfatal myocardial infarction, or nonfatal stroke1.02 (0.94–1.11)0.63
Subset with severe hypoglycemiaCardiovascular death, nonfatal myocardial infarction, or nonfatal stroke1.58 (1.24–2.02)<0.001
Total mortality1.74 (1.39–2.19)<0.001
Cardiovascular death1.71 (1.27–2.30)<0.001
Arrhythmic death1.77 (1.17–2.67)<0.001